Dynavax Technologies reported $219.96M in Loan Capital for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Adma Biologics ADMA:US $ 94.36M 0.49M
Alexion Pharmaceuticals ALXN:US $ 2388.8M 30.8M
Amgen AMGN:US $ 33291M 4833M
AstraZeneca AZN:LN 28939M 4338M
Astrazeneca AZN:US 28.94B 4.34B
Biogen BIIB:US $ 6272.3M 996.9M
Biomarin Pharmaceutical BMRN:US $ 1078.09M 0.98M
Bristol Myers Squibb BMY:US $ 39677M 2826M
Glaxosmithkline GSK:US $ 20736M 294M
Gw Pharmaceuticals GWPH:US $ 14.16M 0.14M
Idera Pharmaceuticals IDRA:US $ 0M 0M
Minerva Neurosciences NERV:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 330.7M 4.4M
Novartis NOVN:VX SF 24715M 1776M
Regeneron Pharmaceuticals REGN:US $ 1979.6M 0.4M
Sarepta Therapeutics SRPT:US $ 1094.91M 1.93M
Vertex Pharmaceuticals VRTX:US $ 513.26M 11.67M